Regeneron Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2024 Annual Meeting of Shareholders held on June 14, 2024. The filing was submitted on June 20, 2024. Regeneron Pharmaceuticals, Inc. is incorporated in New York and its common stock trades on the NASDAQ Global Select Market under the symbol REGN.
Financial Metrics
This filing is a current report regarding shareholder voting outcomes and does not contain financial statements. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Shareholders voted on four proposals at the annual meeting. All proposals were approved.
- Proposal 1 (Election of Directors): Five nominees were elected. Notably, Arthur F. Ryan received significant opposition with 31,288,101 votes against, while other nominees received fewer than 10 million votes against.
- Proposal 2 (Auditor Ratification): Shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Proposal 3 (Executive Compensation): The advisory vote on executive compensation was approved.
- Proposal 4 (Shareholder Proposal): A non-binding proposal requesting simple majority voting requirements was approved.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific reasons for the high number of "Against" votes (31.3 million) cast for director nominee Arthur F. Ryan compared to other nominees.
- Confirm the implementation timeline for the simple majority voting requirements approved in Proposal 4.
- Review the definitive proxy statement (Schedule 14A) filed on April 25, 2024, for detailed executive compensation data referenced in Proposal 3.